A 46-year-old from Ivory Coast with HIV-2 is seen in clinic for a follow-up visit after having virologic failure with tenofovir DF-emtricitabine and lopinavir-ritonavir. The decision is made to modify the antiretroviral regimen. Drug resistance testing for HIV-2 is not available.
Which one of the following is TRUE regarding treatment of HIV-2 with the integrase strand transfer inhibitors (INSTIs) bictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir?
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 27th, 2023
September 27th, 2023
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5